• Exelixis, Inc. has reported first-quarter 2026 results, with revenue of US$610.81 million and net income of US$210.47 million, alongside higher basic and diluted earnings per share than a year earlier.
• The widening gap between revenue and profit compared with the prior-year quarter points to improving operational efficiency and earnings power from Exelixis’s oncology portfolio.
• Next, we’ll explore how this margin improvement and earnings growth intersect with Exelixis’s existing investment narrative centered on oncology expansion.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Exelixis Investment Narrative Recap

To own Exelixis, you need to believe its oncology portfolio can offset heavy reliance on CABOMETYX while managing pricing and competitive pressures. The Q1 2026 beat, with higher revenue and net income, supports the near term earnings story but does not materially change the key short term catalyst around zanzalintinib regulatory progress or the biggest risk of future erosion in CABOMETYX economics and margins.

The most relevant recent announcement is the US FDA’s acceptance of Exelixis’s NDA for zanzalintinib plus atezolizumab in metastatic colorectal cancer, with a December 3, 2026 PDUFA date. Against the backdrop of stronger Q1 profitability, this filing sits at the heart of the diversification catalyst investors are watching, as it represents a potential step toward reducing revenue concentration in CABOMETYX if the regimen ultimately reaches the market.

Yet while margins are improving today, the growing exposure to discounted 340B sales is something investors should be aware of as it could...

Exelixis’ narrative projects $3.3 billion revenue and $1.1 billion earnings by 2029.

Uncover how Exelixis' forecasts yield a $47.53 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling Exelixis revenue reaching about US$3.8 billion and earnings of roughly US$1.8 billion by 2028, so when you compare those expectations with Q1’s stronger profitability and the ongoing concern about rising 340B discount exposure, you can see how views on the stock can diverge sharply and may shift again as new data and policy developments come through.

Explore 10 other fair value estimates on Exelixis - why the stock might be worth 20% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.